• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Locklear Lisa covered exercise/tax liability with 7,566 shares, decreasing direct ownership by 5% to 144,629 units (SEC Form 4)

    4/3/25 6:00:10 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Locklear Lisa

    (Last) (First) (Middle)
    1951 NW 7TH AVENUE SUITE 520

    (Street)
    MIAMI FL 33136

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Longeveron Inc. [ LGVN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    04/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 04/01/2025 F 7,566(1) D $1.5 144,629(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares withheld to satisfy the tax obligations in connection with the vesting of a restricted stock unit award.
    2. Includes Restricted Stock Units subject to future vesting.
    Remarks:
    /s/ Paul Lehr, attorney-in-fact 04/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LGVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Soffer Rock sold $2,640 worth of shares (2,000 units at $1.32), decreasing direct ownership by 0.86% to 230,034 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      5/27/25 6:52:13 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Hare Joshua sold $7,367 worth of shares (5,250 units at $1.40), decreasing direct ownership by 0.72% to 721,796 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      5/16/25 6:00:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Blass Devin claimed ownership of 121,084 shares (SEC Form 3)

      3 - Longeveron Inc. (0001721484) (Issuer)

      4/21/25 8:05:05 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Longeveron® to Attend BIO International Convention 2025

      Focus on potential partnership and strategic opportunities for the Company's stem cell therapy program for Alzheimer's diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer's disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in the peer reviewed jour

      5/20/25 9:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

      Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. "We're proud to be a Semifinalist team of X

      5/12/25 7:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

      MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

      11/11/24 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neha Motwani Elected to Longeveron® Board of Directors

      MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte

      7/9/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

      MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the

      7/8/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

      SC 13G/A - Longeveron Inc. (0001721484) (Subject)

      11/14/24 4:20:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      7/26/24 4:18:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      4/17/24 4:03:33 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    SEC Filings

    See more
    • SEC Form 144 filed by Longeveron Inc.

      144 - Longeveron Inc. (0001721484) (Subject)

      5/15/25 3:20:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Longeveron Inc. (0001721484) (Filer)

      5/8/25 4:11:13 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Longeveron Inc.

      10-Q - Longeveron Inc. (0001721484) (Filer)

      5/8/25 4:00:27 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Financials

    Live finance-specific insights

    See more
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:      Conference Call Number:    1.877.407.0789 Conference ID:    13752361     Call meTM Feature:  Click HereWebcast:  Click Here     An archived replay of the webcast will be available o

      5/2/25 8:30:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue

      2/28/25 4:04:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:29 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hashad Mohamed Wa'El Ahmed bought $24,999 worth of shares (10,638 units at $2.35), increasing direct ownership by 118% to 19,616 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soffer Rock bought $325,000 worth of shares (138,298 units at $2.35), increasing direct ownership by 197% to 208,534 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Longeveron with a new price target

      ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

      12/6/24 7:54:21 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EF Hutton initiated coverage on Longeveron with a new price target

      EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

      1/5/22 10:22:40 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care